Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation study in female subjects with relapsed ovarian cancer (including
epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).
Approximately 30 to 40 subjects will be administered a combination of conatumumab and
birinapant.
In the initial dose-escalation stage of the study, adult female subjects will receive
conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to
determine the MTD of birinapant when administered with a fixed dose of conatumumab.
In safety expansion stage, adult female subjects will receive conatumumab in combination with
birinapant at the MTD of the combination.